Bayer Stock Catches a Double Tailwind as Ruveon and Supreme Court Move in Tandem

Bayer withdraws antidumping petition on glyphosate while US Supreme Court seeks DOJ opinion on Roundup preemption—shares rally 27% in 30 days.

The past week has handed Bayer shareholders a rare combination of developments that, taken together, are reshaping the narrative around the embattled chemicals and pharmaceuticals group. From a voluntary withdrawal of a US antidumping petition on glyphosate to a fresh signal from the Supreme Court in Washington, the company is chipping away at two of the most persistent sources of legal and commercial friction.

On Friday, Bayer’s subsidiary Ruveon formally rescinded its application for antidumping duties on imported glyphosate. The move was welcomed by the National Corn Growers Association, whose president Jed Bower noted that US farmers are already grappling with high input costs. Tariffs on the active ingredient would have only compounded their burden. By pulling the request, Bayer signals a willingness to de-escalate tensions with its own domestic customer base — a pragmatic step that analysts say could improve long-term relationships ahead of the spring planting season.

That commercial gesture coincides with a far higher-stakes legal manoeuvre. The US Supreme Court has asked the Department of Justice to submit its position on Bayer’s appeal concerning federal preemption of state-level Roundup lawsuits. At issue is whether the Environmental Protection Agency’s approval of glyphosate bars state tort claims, a point that could determine the fate of more than 67,000 open cases. If the DOJ sides with Bayer, the company may finally have a legal architecture to shut down future waves of litigation. Bayer has already paid roughly $10 billion to resolve pre-2020 claims, and a favourable Supreme Court ruling would effectively cap that era.

The market has begun pricing in this possibility. Bayer’s stock closed Friday at €48.06, a gain of 0.97% on the day, extending a 30-day rally of 27.31%. The shares have climbed 29.86% since the start of the year, though they remain roughly 10.8% below a 52-week high of €53.86 touched in early July. Market capitalisation now stands at €46.88 billion. The equity’s relative strength index of 59.3 suggests the rally has not yet pushed the stock into overbought territory, leaving room for either further upside or a healthy consolidation.

Behind the legal headlines, Bayer is quietly strengthening its pharmaceutical pipeline. The group has announced new clinical trial partnerships with Henry Ford Health and the University of Colorado, part of a strategy to reduce dependence on any single blockbuster drug and accelerate development through top-tier academic collaborators in the US. With the balance sheet still carrying a heavy debt load, operational muscle in pharma represents a crucial second pillar alongside any legal relief.

Not all the noise is constructive. Simon Rolfes, the sporting director of Bayer 04 Leverkusen, publicly criticised the city council of Monheim for again rejecting the football club’s planned campus — the second such rejection. Separately, an unverified report from a German monitoring group alleged that Bayer subsidiary Monsanto is supplying elemental phosphorus — used in white phosphorus and glyphosate — to Israel, though no evidence of military use has been provided and neither Bayer nor authorities have confirmed the claim. Meanwhile, a study published in Environmental Science: Processes & Impacts warns that fully remediating PFAS contamination in Europe could cost up to €183 billion annually, with even the best-case scenario removing less than 2% of emissions. The research does not single out Bayer directly, but it adds to the regulatory scrutiny that hangs over the entire agrochemical sector.

For investors, however, the twin developments from Ruveon and the Supreme Court are the clearest signals yet that Bayer is actively trying to untangle the knot of glyphosate litigation — on both the commercial and judicial fronts. The stock’s recovery from last summer’s lows is no longer a flicker of hope; it now has two distinct, concrete threads supporting it. How those threads weave together in the coming months will determine whether this rally has staying power or needs another catalyst.